SIBTECH, INC.

Basic Information

115A Commerce Drive
Brookfield, CT, 06804-3400

Company Profile

n/a

Additional Details

Field Value
DUNS: 966566465
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Clinical development of 18F PET tracer for imaging VEGF receptors

    Amount: $222,920.00

    The overall goal of this collaborative Fast-Track project is clinical development of a novel 18F PET tracer for molecular imaging of receptors for vascular endothelial growth factor (VEGFR). This rece ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. SBIR TOPIC 85 PHASE I, DEVELOPMENT OF MOLECULAR IMAGING AGENTS AND METHODS TO DETECT HIGH RISK ATHEROSCLEROTIC PLAQUE 9/8/2014- 9/7/2015

    Amount: $224,944.00

    Not Available

    SBIR Phase I 2014 Department of Health and Human Services
  3. Targeted photoacoustic imaging of VEGF receptors in angiogenic vasculature

    Amount: $286,918.00

    DESCRIPTION (provided by applicant): We propose to develop a contrast agent for photoacoustic imaging targeted to the receptors of vascular endothelial growth factor (VEGFR), so it can be accumulated ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Targeted delivery of Lu-177 to tumor vasculature

    Amount: $1,791,385.00

    DESCRIPTION (provided by applicant): Currently available anti-angiogenic drugs inhibit VEGF/VEGFR signaling, which leads to transient vascular regression followed by rebound of drug-resistant vasculat ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. Targeted Delivery of Cardioprotective Drugs

    Amount: $385,462.00

    DESCRIPTION (provided by applicant): Myocardial infarction is a disabling disease, with infarct size being a major determinant of mortality. To limit infarct size and improve functional recovery, the ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Targeted delivery of Lu-177 to tumor vasculature

    Amount: $286,382.00

    DESCRIPTION (provided by applicant): Our goal is to develop a targeted anti-cancer 177Lu radiotherapeutic agent that localizes to a tumor via receptor- mediated uptake by endothelial cells in the ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. Targeting GRP78/BIP As An Adjunct Therapy For EGFR-positive Breast Cancer

    Amount: $245,842.00

    DESCRIPTION (provided by applicant): Drug-resistant breast cancer cells are the main cause of recurrent disease. One mechanism of cancer cell survival and drug resistance is mobilization of GRP78/BiP, ...

    SBIR Phase I 2008 Department of Health and Human Services
  8. Targeted Molecular Radiotherapy for Rheumatoid Arthritis

    Amount: $99,909.00

    The progression of rheumatoid arthritis (RA), specifically, the growth of the bone-destroying pannus in RA joints, depends on the formation of new blood vessels, whose growth is mediated primarily by ...

    SBIR Phase I 2008 Department of Energy
  9. Targeting anti-apoptotic drugs to failing cardiomyocytes

    Amount: $187,130.00

    DESCRIPTION (provided by applicant): Heart failure is the major cause of morbidity and mortality worldwide. It is recognized that cardiomyocyte apoptosis plays an important role in heart failure. Intr ...

    SBIR Phase I 2007 Department of Health and Human Services
  10. Targeted Delivery of Anthrax Inhibitors

    Amount: $213,510.00

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a system for targeted delivery of anthrax toxin inhibitors. Antibiotic treatment currently approved as a post-exposu ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government